Regulus Therapeutics
在场
Regulus Therapeutics 是一家在股票代码 RGLS (US) 下上市的公司。
高管
查看带有其 23 名主要高管的组织结构图
Regulus Therapeutics 搜索最多的简介
- Joseph Hagan, President, Chief Executive Officer and Director
- David Baltimore, Director
- Kathryn Collier, Director
高管在Regulus Therapeutics变化
- Rekha Garg 曾任 Senior Vice President, Clinical Development and Regulatory, 现升职为 Chief Medical Officer (新闻发布的2024五月17号).
创建提醒
跟踪 Regulus Therapeutics 的高管变动
生物技术
Regulus Therapeutics 拥有 2,291 家竞争者，其中包括 Lonza (瑞士)、Eurofins (卢森堡) 和 Deepull (西班牙)。
Popular M&A news in 生物技术
- Restor3d 刚刚宣布为 70 筹款数百万美元。 (公布2024六月8号).
- Vilya 刚刚宣布为 71 筹款数百万美元。 (公布2024六月6号).
- BioNTech 刚刚宣布为 145 筹款数百万美元。 (公布2024六月5号).
生物技术 行业的其他推荐联系人
消息
Regulus Therapeutics 的最新新闻稿
- Press Releases - Regulus Therapeutics
- Press Releases - Regulus Therapeutics
- Press Releases - Regulus Therapeutics
- Press Releases - Regulus Therapeutics
- Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference | Regulus Therapeutics Inc.
- Regulus Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates | Regulus Therapeutics Inc.
- Regulus Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Regulus Therapeutics Inc.
- Regulus Therapeutics Announces Timing for First Quarter 2022 Financial Results Webcast and Conference Call | Regulus Therapeutics Inc.
- Regulus Therapeutics Announces Initiation of Preclinical Studies in Amyotrophic Lateral Sclerosis under a Collaboration Agreement with Harvard's Brigham and Women's Hospital | Regulus Therapeutics Inc.
- Regulus Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Updates | Regulus Therapeutics Inc.
- View more press releases Close
通过电子邮件
